Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen by Jansen, M.P.H.M. (Maurice) et al.
Oncotarget43412www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 28
Cell-free DNA mutations as biomarkers in breast cancer patients 
receiving tamoxifen
Maurice P.H.M. Jansen1, John W.M. Martens1, Jean C.A. Helmijr1, Corine M. Beaufort1, 
Ronald van Marion2, Niels M.G. Krol2,3, Kim Monkhorst2, Anita M.A.C. Trapman-
Jansen1, Marion E. Meijer-van Gelder1, Marjolein J.A. Weerts1, Diana E. Ramirez-
Ardila1, Hendrikus Jan Dubbink2, John A. Foekens1, Stefan Sleijfer1, Els M.J.J. Berns1
1Department of Medical Oncology and Cancer Genomics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
3Cancer Computational Biology Center, Rotterdam, The Netherlands
Correspondence to: Stefan Sleijfer, email: s.sleijfer@erasmusmc.nl
Keywords: breast cancer, tamoxifen therapy, targeted next generation sequencing, cell-free DNA, disease progression
Received: February 12, 2016    Accepted: May 08, 2016    Published: May 30, 2016
ABSTRACT
The aim was to identify mutations in serum cell-free DNA (cfDNA) associated with 
disease progression on tamoxifen treatment in metastatic breast cancer (MBC). Sera 
available at start of therapy, during therapy and at disease progression were selected 
from 10 estrogen receptor (ER)-positive breast cancer patients. DNA from primary 
tumor and normal tissue and cfDNA from minute amounts of sera were analyzed by 
targeted next generation sequencing (NGS) of  45 genes (1,242 exons). At disease 
progression, stop-gain single nucleotide variants (SNVs) for CREBBP (1 patient) 
and SMAD4 (1 patient) and non-synonymous SNVs for AKAP9 (1 patient), PIK3CA 
(2 patients) and TP53 (2 patients) were found. Mutations in CREBBP and SMAD4 have 
only been occasionally reported in breast cancer. All mutations, except for AKAP9, 
were also present in the primary tumor but not detected in all blood specimens 
preceding progression. More sensitive detection by deeper re-sequencing and digital 
PCR confirmed the occurrence of circulating tumor DNA (ctDNA) and these biomarkers 
in blood specimens.
INTRODUCTION 
It is increasingly appreciated that the genetic make-up 
of tumors forms one of the main determinants for outcome 
to systemic treatments in cancer patients [1]. There is also 
accumulating evidence that primary tumor characteristics 
can greatly differ from those of the metastases [2]. This 
may underlie the relatively poor association of molecular 
characteristics of primary tumors with outcome in MBC. 
It is therefore likely that genetic variants important for 
treatment decision making should be determined in 
specimens from metastatic tumor rather than from primary 
tumor tissue. In addition, the genetic constitution of a tumor 
lesion is not fixed but constantly changes, in particular 
under treatment pressure. As novel DNA mutations can 
cause resistance to systemic treatments, longitudinal 
monitoring of these mutations during treatment is crucial to 
detect resistance at an early stage and, if possible, to adjust 
treatment based on the emerging mutations.
DNA from primary and metastatic tumor cells can 
be detected as cfDNA in the peripheral blood of cancer 
patients. This cfDNA is therefore a very attractive tool to 
establish mutational changes occurring in tumor cells in a 
minimal invasive manner. Its great promise in this respect 
was recently reviewed [3]. For example, in patients with 
metastatic KRAS wild-type colorectal cancer treated 
with an anti-EGFR antibody, blood analyses showed that 
the appearance of KRAS mutants, conferring resistance 
against anti-EGFR antibodies, preceded progressive 
disease with up to 10 months [4]. Likewise, in breast 
cancer patients mutations in the estrogen receptor 
(ESR1) have been hardly detected in primary tumors 
but are currently frequently reported in plasma from 
patients with metastatic disease that acquired resistance 
to aromatase inhibitor therapy [5–8]. In the current study, 
we aimed to identify tumor-specific mutations in cfDNA 
that associate with disease progression on tamoxifen in 
MBC. 
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RESULTS 
Detection of DNA changes
As we were interested in cfDNA mutations that 
potentially associate with treatment outcome in a particular 
patient, we characterized DNA changes in serum taken at 
disease progression in 10 MBC patients who received first-
line tamoxifen (Supplementary Table S1). After applying 
our selection criteria on called variants, 18 cfDNA changes 
were identified at disease progression which were not 
detected in normal tissue DNA nor reported by the 1000 
Genome database. Of these, 3 variants were only seen in 
blood specimens and not in the corresponding primary 
tumor whereas 15 variants were also detectable in the 
primary tumor. Twelve DNA changes in 6 patients were 
shown to associate with treatment outcome (Figure 1). 
Of these, 9 tumor-specific DNA changes were present at 
disease progression and in the primary tumor but not in all 
blood specimens preceding progression (Table 1). 
Pathogenic somatic single nucleotide substitutions 
The 12 DNA changes included 5 synonymous 
and 7 non-synonymous SNVs. Almost all algorithms 
predicted the missense SNVs for CDH1, PIK3CA and 
TP53 (p.V41G; p.R148G) as pathogenic and for AKAP9, 
CREBBP and SMAD4 predominantly as not pathogenic 
(Supplementary Table S2). Moreover, the SNVs in PIK3CA 
and TP53 have been reported as cancer-specific mutations.
Re-sequencing at 1% detection limit of missense 
SNVs 
Next the identified non-synonymous SNVs were 
selected for re-sequencing since only these translate into 
amino acid changes, which might alter the biological 
function of the encoded protein and as a result might 
affect clinical outcome. All specimens were re-sequenced 
for 1 missense SNV found in blood only and 5 missense 
SNVs found in primary tumors at diagnostic levels, 
i.e. higher than 10%. The re-sequencing confirmed the 
initial results for AKAP9 p.H562Q in patient 1, CREBBP 
p.E1321X in patient 6, SMAD4 p.Y353X, TP53 p.V41G, 
and PIK3CA H1047L in patient 7, and TP53 p.R148G 
in patient 8. Moreover, PIK3CA exon 20 re-sequencing 
identified another SNV, i.e. p.H1047R. This SNV was seen 
at disease progression and all other blood specimens of 
patient 1 and in the primary tumors of patients 1, 2, and 7 
(Supplementary Table S3). 
Digital PCR evaluation at 0.05% detection limit 
of PIK3CA mutations
The re-sequencing results for PIK3CA were 
verified by digital PCR using mutation-specific assays 
(Supplementary Table S3). The p.H1047L mutation was 
evaluated and confirmed in all specimens of patients 7 and 
10, but was additionally seen in serum at start of therapy 
of patient 10. The p.H1047R mutation was evaluated in all 
primary tumors as well as in blood specimens of patients 
1 and 2. Digital PCR confirmed the occurrence of this 
mutation in all evaluated blood specimens and primary 
tumors, except in the primary tumor of patient 7.
cfDNA mutations and disease development
For patient 1 additional blood specimens available 
between diagnosis of primary tumor and metastatic lesions 
were evaluated by NGS and digital PCR (Figure 2). 
Re-sequencing demonstrated AKAP9 and PIK3CA 
mutations at similar magnitudes in blood specimens 
taken around the occurrence of metastatic lesions. It also 
detected PIK3CA mutant reads in blood preceding the 
metastasis, however, in less than 10 reads. Digital PCR 
confirmed this PIK3CA mutation in blood taken 6 years 
after diagnosis of primary disease but two years before 
diagnosis of metastatic lesions. At the time metastatic 
lesions were recognized, the blood had a large number of 
copies with this mutation, which dropped after 2 months 
of first-line tamoxifen therapy, but increased towards 
therapy resistance after 6 months treatment. 
DISCUSSION 
This exploratory study is to our knowledge the first 
to report on sequential monitoring of serum cfDNA in a 
homogenous setting of MBC-patients receiving first-line 
tamoxifen therapy. In total 12 variants for 6 patients were 
identified in cfDNA at disease progression, including 
3 variants that were only found in blood specimens 
but not in the primary tumor and 9 variants detected 
in corresponding primary tumor but not in all blood 
specimens preceding progression. Because of their 
putative biological relevance, we confirmed the identified 
missense mutations by re-sequencing and by digital PCR. 
Out of these, missense mutations in PIK3CA, 
TP53, SMAD4 and CREBBP were present both at time of 
progression and in the primary tumor. COSMIC reported 
mutations in breast cancer most frequently in PIK3CA 
and TP53 while occasionally in CREBBP and SMAD4 
with our variants for the latter two genes not earlier 
described. Mutations in all these genes have been found 
in hormone-resistant breast cancer [9]. The presence of 
PIK3CA and TP53 mutations in longitudinally collected 
blood specimens correlated with treatment outcome 
to PI3K-inhibitors and aromatase inhibitors and was 
associated with the clinical course of disease [10, 11]. 
CREBBP and SMAD4 encode proteins that bind to ER 
as co-activator [12] and co-repressor [13], respectively, 
suggesting a putative role in endocrine therapy resistance 
[13, 14]. However, the effect of the CREBBP stop-gain 
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mutation revealed in our study remains to be established. 
The SMAD4 p.Y353X stop-gain mutation resides within 
the MH2 domain, a mutational hotspot [15] related to 
a loss of function, detrimental for TGFb signaling, and 
poor disease outcome [16]. Importantly, above variants at 
time of progression likely reflect only tumor load in the 
blood. The AKAP9 p.H562Q missense mutation was not 
seen in the primary tumor and might have been missed due 
to tumor cell heterogeneity. Alternatively, this mutation 
might originate from metastatic lesions or acquired due 
Figure 1: Study design and discovered DNA changes. Targeted ion-PGM (re-)sequencing was performed on DNA isolated from 
primary tumors and blood specimens from 10 metastatic breast cancer patients who received tamoxifen as first-line therapy. Cell-free 
DNA (cfDNA) was isolated from 400 µl serum taken at start (Ss), during therapy (St) and at disease progression (Sp). Analysis revealed 
12 biomarkers including 9 single nucleotide variants (SNVs) detected at progression and in primary tumor but not in all  preceding blood 
specimens. The SNVs originating from the primary tumor are presented in red when only seen at Sp, in green when seen at Ss and Sp, and 
in blue when seen at St and Sp. 
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Figure 2: cfDNA missense mutations and disease development. The AKAP9 and PIK3CA mutations of patient 1 were evaluated 
in blood specimens during the course of disease. Sera collected five years after clinical diagnosis of breast cancer were evaluated by ion-
PGM resequencing and for PIK3CA in duplicate by digital PCR (dPCR). The p.H1047R mutation was observed at low magnitude in blood 
taken five years after diagnosis of primary disease and already two years before radiological diagnosis of metastatic lesions. Although 
sometimes low numbers of PIK3CA mutant copies were detected, all were independently observed after ion-PGM resequencing and in two 
separate digital PCR reactions. All proportions except for the sample at 5y11m were above the limit of detection.
Table 1: 12 cfDNA mutations identified as biomarkers in 6 metastatic breast cancer patients receiving first-line 
tamoxifen therapy1
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to treatment pressure. Variants in AKAP9 have been 
described repeatedly in COSMIC and as SNPs associated 
with increased breast cancer risk [17], but the particular 
variant found here has not yet been reported. It is currently 
unknown whether, and if so, to which extent, all missense 
mutations actually contribute to resistance against 
tamoxifen. Many of the mutations are probably bystander 
mutations due to genomic instability. Therapy resistance, 
however, may select for tumor cells with specific 
mutations adapting these cells to the hostile environment, 
resulting in the survival of fittest and ultimately driving 
tumor progression [18].  
Our study differs from previous studies using ion-
PGM targeted NGS on cancer tissue and liquid biopsies 
to identify tumor-specific DNA changes. Earlier studies 
[19– 21] evaluated 200 amplicons of the commercially 
available hotspot cancer panel whereas we examined 
fifteen-fold more amplicons. These studies detected 
mutations in both plasma and tissue for 27 of 34 cancer 
patients [20], or like our study, in half of the cancer 
patients [19, 21] and evaluated plasma specimens 
collected within a 16 month time-frame after primary 
tumor tissue was obtained. We instead sequenced and 
identified mutations in minute cfDNA amounts isolated 
from serum collected at least 3 years after diagnosis of 
primary disease. Mutations in low DNA amounts might be 
missed due to the  limited number of genomic equivalents 
present and corresponding higher limit of detection. 
Retrospective studies, such as our own, collected mainly 
limited blood quantities which will often result in minute 
cfDNA amounts available for analysis. Furthermore, our 
serum samples have been stored at –80°C for more than 
18 years, demonstrating that long-term stored routinely 
collected sera are suitable for cfDNA isolation and 
subsequent molecular characterization. 
To define ctDNA mutations in blood associated 
with disease progression on tamoxifen treatment, we 
screened for biomarkers seen at progression and the 
corresponding primary tumor but not in all preceding 
blood specimens in a particular patient. The mutation 
detection in blood depends on cfDNA quantities, with 
these quantities changing in time and reflecting tumor 
load in the course of disease. Our study showed overall no 
significant differences in blood cfDNA yields at different 
time-points, however, most mutations were detected 
in patients with the highest DNA yields at progression. 
Deeper re-sequencing confirmed the presence of the 
6 missense SNVs in specimens of individual patients in 
which they were initially reported and absence from those 
which initially lack them. It also discovered an additional 
PIK3CA mutation, and examination of sequence reads 
revealed that the p.H1047R mutation was originally 
present in respective specimens but not called due to 
stringent settings, indicating that current thresholds are 
suboptimal for rare variant detection in cfDNA [19, 22]. 
Digital PCR independently identified both PIK3CA 
mutations in blood specimens at higher frequencies 
than revealed by NGS and in additional specimens and 
as proof-of-principle even in blood taken years before 
diagnosis of the metastatic lesions. 
In conclusion, our study demonstrates that 
targeted ion-PGM sequencing of cfDNA is applicable to 
discover mutations in archived serum samples. Deeper 
re-sequencing and digital PCR analyses enables more 
sensitive detection and monitoring of specific mutations 
in sequential blood specimens even in samples stored for 
over 18 years and in minute amounts of cfDNA. Further 
studies are warranted to investigate whether detection 
of ctDNA in tamoxifen-treated metastatic breast cancer 
patients can be used to detect disease progression at an 
early stage and whether the identified variants play a role 
in tamoxifen resistance.  
MATERIALS AND METHODS 
Materials and methods are described briefly below, 
details are found in the appendix.
Patient and sample collection 
This retrospective study investigated fresh frozen 
primary tumor tissue and sequential sera taken from 10 
MBC patients who received tamoxifen as first-line therapy 
for distant metastatic disease (Figure 1). Blood specimens 
were selected at start of tamoxifen therapy (Ss), during 
therapy (St), and at disease progression (Sp). From 6 
patients formalin fixed paraffin embedded (FFPE) macro-
dissected normal tissue was available and analyzed. The 
study was approved by the medical ethics committee 
(MEC 02.953), performed according to the Code of 
Conduct of Medical Scientific Societies (www.federa.
org/codes-conduct) and followed REMARK guidelines 
where possible [23]. Clinicopathological characteristics 
are presented in Supplementary Table S4.
DNA isolation, quantification, and sequencing
DNA from tumor and normal tissue specimens 
was extracted as described previously [24, 25]. The 
MagnaPure Compact nucleic acid isolation kit (Roche 
Diagnostics) was applied to isolate cfDNA from 400 µl 
serum. DNA yields and concentrations were quantified 
with a Qubit® 2.0 fluorometer (Thermo Scientific). The 
cfDNA input amounts of each sample were used to 
establish the genomic equivalents and limits of detection 
for subsequent molecular analyses (Supplementary Tables 
S5 and S6). Semiconductor sequencing was performed 
using the Ion Torrent Personal Genome Machine (Ion-
PGM) and consumables, kits, software packages and 
protocols provided by the manufacturer (Thermo 
Scientific). Briefly, 10 ng tissue DNA and minute amounts 
cfDNA (range: 165-573 pg) were used as input for library 
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preparation and sequenced with a custom-made gene 
panel. Ion AmpliSeq Library Preparation Kit 2 and Ion 
PGM Template OT2 200 kit were applied to generate 
libraries and templates, respectively. Ion Sequencing Kit 
v2 was used for sequencing on an Ion 318 chip. 
Custom gene panel
The 45-gene panel (Supplementary Table S2) 
included the most frequently mutated genes for breast, 
colon, prostate and ovarian cancer reported in the catalogue 
of somatic mutations in cancer (Cosmic Release 67; 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). 
Thirty-nine genes were sequenced for all exons, 6 
oncogenes for hotspot exons only. In total 3,106 amplicons 
(i.e. 1,242 exons; ~255kb) were sequenced up to a read 
depth of 5,000x.
Bio-informatics for variant detection and evaluation 
Raw data analyses, base calling and alignment were 
performed using Torrent Suite v4.0. Somatic low 
stringency filtering was applied in Variant Caller 
v4.16 (VC) to detect DNA changes when compared 
to reference genome hg19 (build 37). Variants were 
annotated by a custom pipeline including ANNOVAR 
(openbioinformatics.org/annovar) within Galaxy 
(galaxyproject.org). Only exonic variants with frequencies 
of 1% or higher and above the cfDNA-specific limit of 
detection were selected. Uniquely identified variants 
and those found in sequenced normal DNA or reported 
within the 1000-Genome database were excluded. These 
variants had to be sequenced without strand bias at a read 
depth of 100x or more and showing at least 10 mutant 
reads. Integrative Genomics Viewer (IGV) (http://www.
broadinstitute.org/igv) was used for manual examination. 
Identified SNVs were evaluated with different in silico 
algorithms to predict the pathogenicity of the SNV on 
protein function. These tools are embedded in ANNOVAR 
and included SIFT, PolyPhen2, MutationTaster, 
FATHMM, GERP++, SiPhy and PhyloP [26].
Re-sequencing and digital PCR analysis
Exons of selected non-synonymous SNVs were 
re-sequenced for all specimens by ion-PGM after 
independent library preparation up to 100,000 reads 
depth, and evaluation was performed similar to the 
initial analysis. The PIK3CA genotype was verified with 
Taqman p.H1047L- and p.H1047R-specific assays and 
the QuantStudio™ 3D Digital PCR system (Thermo 
Scientific). Reaction mixtures, including tumor or serum 
DNA and QuantStudio™ 3D Digital PCR Master Mix, 
were loaded on digital PCR chips with 20,000 wells, 
and cycled under standard conditions for 40 cycles. 
QuantStudio™ 3D analysisSuite™ determined the 
proportion mutant and wild-type templates.
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